Andersen-Tawil syndrome primary prevention

Andersen-Tawil syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Andersen-Tawil syndrome from other Diseases
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Tertiary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Andersen-Tawil syndrome primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
slides
Images
American Roentgen Ray Society Images of Andersen-Tawil syndrome primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Andersen-Tawil syndrome primary prevention
CDC on Andersen-Tawil syndrome primary prevention
Andersen-Tawil syndrome primary prevention in the news
Blogs on Andersen-Tawil syndrome primary prevention
Directions to Hospitals Treating Andersen-Tawil syndrome
Risk calculators and risk factors for Andersen-Tawil syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Primary Prevention

Genetic Counselling

ATS is inherited in an autosomal dominant manner. At least 50% of individuals diagnosed with ATS have anaffected parent. Up to 50% of cases are caused by de novo mutations. Each child of an individual with ATS has a 50% chance of inheriting the disorder. Prenatal diagnosis for pregnancies at increased risk is possible if the disease-causing mutation has been identified in an affected family member.

• Parents of a proband: At least 50% of individuals diagnosed with ATS have an affected parent. A proband with ATS may have the disorder as the result of a de novo gene mutation. The proportion of cases caused by de novo mutations may be as high as 50%. Recommendations for the evaluation of parents of a proband with an apparent de novo mutation include a detailed neurologic and cardiologic evaluation, 12-lead ECG, 24-hour Holter monitoring, and molecular genetic testing for the KCNJ2 mutation identified in the proband.
• Sibs of a proband: The risk to the sibs of the proband depends on the genetic status of the proband's parents. If a parent of the proband is affected and/or has the KCNJ2 mutation identified in the proband, the risk to the sibs of inheriting the mutation is 50%. When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low. If a disease-causing mutation cannot be detected in the DNA extracted from the leukocytes of either parent, two possible explanations are germline mosaicism in a parent or a de novo mutation in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.
• Offspring of a proband: Each child of an individual with ATS has a 50% chance of inheriting the mutation.
• Other family members of a proband: The risk to other family members depends on the status of the proband's parents. If a parent is affected, his or her family members are at risk.

Overview

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include:

• [Measure1]
• [Measure2]
• [Measure3]

References

Template:WikiDoc Sources CME Category::Cardiology